## 2-(4-methoxyphenyl)-1-(2-methylprop-2-enyl)benzimidazole
This compound is a benzimidazole derivative with a specific molecular structure:
* **Benzimidazole core:** A nitrogen-containing heterocyclic ring system, common in pharmaceuticals.
* **Methoxyphenyl substitution:** A phenyl group with a methoxy (OCH3) substituent, which can influence the compound's properties.
* **2-methylprop-2-enyl substitution:** A side chain with a double bond (alkene) and a methyl group. This can affect the molecule's shape and reactivity.
**Importance for Research:**
Specific research interests surrounding this compound may vary, but generally, benzimidazoles have a wide range of biological activities, including:
* **Anti-cancer properties:** Several benzimidazole derivatives have shown promising activity against different types of cancer. The methoxyphenyl and 2-methylprop-2-enyl substituents may modify the compound's interaction with specific cancer targets.
* **Antimicrobial activity:** Benzimidazoles are known to possess antibacterial and antifungal properties. This compound might exhibit improved efficacy or target different pathogens due to its unique structure.
* **Anti-inflammatory activity:** Benzimidazoles can modulate inflammatory processes. This specific derivative might offer specific anti-inflammatory effects due to its substituents.
* **Other therapeutic potential:** The compound could be explored for its potential in areas like anti-viral, anti-parasitic, or neuroprotective research.
**Research areas of interest:**
* **Structure-activity relationship:** Understanding how the specific substituents on the benzimidazole core influence the compound's biological activity.
* **Synthesis and optimization:** Developing efficient synthetic methods to produce the compound and explore structural variations.
* **Pharmacological studies:** Evaluating the compound's efficacy, mechanism of action, and potential toxicity in various in vitro and in vivo models.
* **Drug development:** Furthering the research to potentially develop this compound into a new therapeutic agent.
**Overall, the specific importance of 2-(4-methoxyphenyl)-1-(2-methylprop-2-enyl)benzimidazole lies in its potential for development as a new drug or research tool, given the wide range of biological activities associated with benzimidazole derivatives.** However, further research is needed to fully understand its properties and applications.
ID Source | ID |
---|---|
PubMed CID | 661309 |
CHEMBL ID | 1334561 |
CHEBI ID | 112173 |
Synonym |
---|
AKOS001138800 |
MLS000037195 , |
smr000041990 |
NCGC00020297-01 |
CHEBI:112173 |
2-(4-methoxyphenyl)-1-(2-methylprop-2-enyl)benzimidazole |
NCGC00020297-02 |
STK738152 |
2-(4-methoxyphenyl)-1-(2-methylprop-2-en-1-yl)-1h-benzimidazole |
CCG-142723 |
HMS2306C03 |
CHEMBL1334561 |
Q27192275 |
2-(4-methoxyphenyl)-1-(2-methylprop-2-en-1-yl)-1h-1,3-benzodiazole |
Z57300225 |
Class | Description |
---|---|
benzimidazoles | An organic heterocyclic compound containing a benzene ring fused to an imidazole ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 23.9341 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 31.6228 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
ClpP | Bacillus subtilis | Potency | 15.8489 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 79.4328 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
TDP1 protein | Homo sapiens (human) | Potency | 13.7882 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 0.5012 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 19.9526 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 12.5893 | 0.0013 | 7.7625 | 44.6684 | AID914; AID915 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 11.2202 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 22.3872 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0018 | 15.6638 | 39.8107 | AID894 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 22.3872 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
geminin | Homo sapiens (human) | Potency | 29.0929 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |